Biology of haemostasis disorders: Thrombin time

Aim
The National Salaried Workers’ Health Insurance Fund (CNAMTS) asked HAS to assess the value of the different laboratory tests for haemostasis abnormalities with a view to updating the section in the Nomenclature of Procedures in Laboratory Medicine (NABM) containing the  procedures  in  laboratory  medicine  for  measuring  abnormalities  of  haemostasis (subsection 5-02). One of those tests is the thrombin time (TT), an NABM procedure, which is a global test for the investigation of fibrin formation. The TT is the clotting time of citrated platelet-poor plasma (PPP) at 37°C in the presence of thrombin. Clot formation could be detected by chronometric, electromechanical or optical methods. A test of correction by adding control plasma can be carried out: the absence of any correction in TT indicates that unfractionated heparin is present in the sample. Historically, TT was used to make a preoperative assessment of haemostasis, investigate haemorrhagic syndrome or to detect the presence of unfractionated heparin in the sample.

Conclusions and results
According to the different documents analysed, TT is not recommended for use in the preoperative assessment of the risk of haemorrhage, the investigation of disseminated intravascular coagulation (DIC), the follow-up of heparin treatments, or for the diagnosis of other disorders such as von Willebrand’s disease. It is still proposed for the diagnosis of rare congenital  fibrinogen  abnormalities.  It  should  be  noted  that  it  is  the  determination  of fibrinogen which is recommended in practice, and that this determination is already an NABM procedure. In conclusion, TT is not advocated either for preoperative assessment of the risk of haemorrhage or for the investigation of haemorrhagic syndrome.

Recommendations
On the basis of the literature identified and analysed, TT has been shown to be a procedure which should no longer be used in current practice.

Methods
This assessment is based on a critical analysis of the literature carried out by the Haute Autorité de Santé, and reviewed by experts in haemostasis. It takes into account the arguments of a group of experts assembled by CNAMTS on which CNAMTS based its request. The assessment of this procedure is based on a critical analysis of the literature consisting of nine guidelines relating to disorders associated with the prescribing conditions (but no document recommending TT), and the review by three experts in haemostasis.

INAHTA Brief issue: 2012/085

Agency: HAS, Haute Autorité de Santé
(Formerly:

Aurélie Pacull)
View contact details


More about this report:
INAHTA Brief in pdf

Reference:

http://www.has-sante.fr/portail/jcms/c_1009982/fr/biologie-des-anomalies-de- lhemostase

" alt="http://www.has-sante.fr/portail/jcms/c_1009982/fr/biologie-des-anomalies-de">http://www.has-sante.fr/portail/jcms/c_1009982/fr/biologie-des-anomalies-de- lhemostase

">Webpage lhemostase


Other publications:
from HAS


Glossary, Acronyms & Publications:
HTA Glossary
List of acronyms
Publication type information